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Summary 
Over the past 30 years there has been a vast change in the manufacture of "specials" within theN ational 
Health Service. From being primitive, badly equipped units situated in the basement of nearly all 
hospitals, N.H.S. production units have changed to pt:.rpose built, hi-tech units licensed by the 
Medicines Control Agency, providing a fast, efficient and validated "specials" service. Although non-
profit making organisations, N.H.S. Production units have to be self-financing. Thus staff costs, 
overheads and replacement of equipment must be financed by sales. Production pharmacists in the 
N.H.S. are now working together to rationalise the produ:::t list within their units. Certain units have 
taken over the roel of national supplier for items and instead of duplicating effort, other units will buy 
from them. 
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Introduction 
In the mid to late 60's, virtually every hospital 
pharmacy department had its own small production 
unit. These were usually situated in the basement 
of the hospital, in close proximity to the pharmacy 
and conditions were often primitive. All types of 
sterile and non-sterile products were manufactured, 
often using very old machinery, and much of the 
tablet pre-packing was done by hand, using 
dispensing triangles. Sterile production units in 
those days generally produced little more that 
Normal Saline and Dextrose infusions in 500 ml 
glass bottles together with a few ampoules and eye 
drops. 
There was no proper costing carried out on these 
exercises so nobody knew if the products could 
have been bought more cheaply from industry. 
Controls and testing procedures were often 
rudimentary. Production was just another facet of 
pharmacy and every hospital that did not have a 
production unit, however primitive, was thought 
to be missing a vital area of post-registration 
training. Professional expertise alone was 
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considered to provide sufficient safeguards for what 
was literally dispensing on a large scale and no 
outside regulatory body was concerned. 
In 1968 the government produced a piece of 
legislation which was designated: "An act to make 
new provisions with respect to medicinal products 
and related matters, and for purposes connected 
therewith."1 This legislation was called The 
Medicines Act 1968 and its publication has had a 
profound effect on the Pharmaceutical profession 
in the United Kingdom ever since. The purpose of 
the act is : "To control, by a licensing system, the 
safety, quality and efficacy of medicinal products. "1 
At this point manufacture of pharmaceuticals in 
hospital units was covered by what is known as 
"crown immunity" and did not require official 
licensing, however, as there could be no justification 
for lower standards applying in hospital units than 
in cm:unercial undertakings the spirit of the act was 
applied to hospital units and they were expected to 
conform to the new standards. 
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The desirability of this course was emphasised by 
the Medicines Commission in their report on the 
preparation of infusion fluids following w~1at is 
known as the "Devenport Incident" in 1972. This 
was an incident when 5 people died in a Plymouth 
hospital following the infusion of a contambated 
batch of Dextrose 5%. This was actually a 
commercially prepared infusion but the hospital 
was not absolved of all responsibility as it was felt 
they should have examined the infusions before 
issuing them to the wards. 
The Commission stated : " ...... too many people 
believe that sterilisation of fluids is easily achieved 
with simple plant operated by men of little skill 
undertheminimumofsupervision,aviewwbchis 
wrong in every respect."2 
An interim report by Lord Rosenheim in 1972 
concerned with the same incident recommended, 
in particular, that: "Control of hospital manufacture 
should be no less rigorous than that which applies 
to pharmaceutical firms who are required :o be 
licensed under the Medicines Act."3 
Accordingly, a system of inspection of hospital 
manufacturing units was implemented. At first 
this was on an informal basis, licenses not being 
required. But it had profound implications fer the 
hospital service. Many units were closed dovrn as 
being unsuitable and those which remained open, 
after extensive modification, went in one of two 
ways. Firstly, in the late 1970's the large scale 
hospital production unit appeared. These :mits 
were able to manufacture sterile fluids on a near 
commercial scale and were, in essence, in 
competition with industry. There were not too 
many of this type of unit but Parkfields in the West 
Midlands and Clatter bridge in the Wirral were two 
such. But the main type of unit to appear was '-V hat 
we call the "Specials" unit. 
What is a special? 
As a general rule, the Medicines Act 1968 requires all 
dealings in medicinal products to be in accordance with 
product licences and all manufacturers of medicinal 
products to hold a manufacturer's licence. 
They do, however, recognise that practitioners may 
need to prescribe medicines that are not available as 
licensed products. Undersuchcircumstancestheprcduct 
can be prepared in a pharmacy registered with the 
PharmaceuticalSocietyorinahospital pharmacy under 
the supervision of a Pharmacist 
This is under what is called a section 10 exemFtion 
from the regulations and enables a small amou_o.t of 
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preparation, for immediate use. There are strict 
guidelines on the amount of preparation permitted 
under this exemption, for example : 
20 packs of a non-sterile liquid, antiseptic or cream, 
100 capsules or suppositories, 
10 packs of terminally sterilised products, this 
includes eye drops, injections, infusions and sterile 
creams; 
25 packs of repackaged tablets, capsules or liquids. 4 
Such items are said to be extemporaneously 
dispensed. 
It is generally not permitted to prepare" aseptically" 
manipulated products for stock at all. Unless made 
in a licensed unit, these should be for immediate 
use only. 
For all items covered by a section 10 exemption there 
is a limit of one batch per month prepared for stock 
Anacceptablelevel of quality assurance is still required 
and products should be made in conditions which 
comply with good manufacturing and dispensing 
practices and should be regularly audited by quality 
control staff. In addition, unless substantiated by 
stability data, the maximum permitted shelf life for 
these preparations is 28 days. Alternatively, the 
pharmacist or practitioner may order the product from 
the appropriately licensed manufacturer. 
"Specials" are defined as Medicinal products in respect 
of which a Product Licence is not in existence but which 
may have been made by the holder of a special 
manufacturer's licence, to the order of a practitioner, for 
administration to a particular patient.4 
Until this year commercial manufacture, even in 
licensed units, had to be by, or under the supervision 
of a pharmacist but since the introduction of European 
licensing requirements this is no longer the case.5 
Manufacture under the section lOexemptionhowever 
remains under the auspices of a pharmacist. 
Itislicencesissued underthese 1994 regulations and those 
which these regulations superseded that are commonly 
referred to as "specials" licenses and the products made 
under there authority are termed "specials". 
A "special" can be: 
- An unusual formulation of a product that is only 
available in certain licensed forms. 
An unusual strength. 
An unusual combination of products. 
A preservative-free version of an eye-drop A 
discontinued product. 
AnitemavailableoverseasbutnotmarketedinBritain. 
- Products made to order due to the temporary 
unavailability of the licensed form. 
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The Present Situation 
Things changed again in 1990 in Great Britain and 
1992 in Northern Ireland when crown exemption 
was removed and all units, including those situated 
in hospital pharmacies, were required to apply for 
manufacturers licences or to cease manufacture. 
Again more units closed leaving a nucleus of 
speciallybuilt,highqualityunitswithintheNational 
Health Service. 
These units were formally inspected by the 
Medicines Inspectors and, if the standards were 
met, were issued with official licences. Henceforth 
there would be absolutely no difference between 
Health Service units and commercial concerns. 
It would be difficult to compare the modern day 
units with those of the late 60's. Most are purpose 
built, designed to the highest standards, and fitted 
with expensive, high quality air handling plants 
providing clean or sterile air to the working 
environment. The operators more resemble 
spacemen than pharmacists or the technicians in 
their one piece all encompassing suits, headgear, 
masks and gloves. 
There are currently 212 holders of specials licenses 
issued by the Medicines Control Agency. Of these 
licenses, 123 are held by National Health Service 
hospitals and 99 by industrial concerns. About a 
dozen of these industrial concerns supply a 
commercial specials service. 
It must be borne in mind that the onus is on the 
purchasing pharmacist, rather then the 
manufacturer, to ensure that any unlicensed 
medicines purchased are up to standard. Due to the 
increased significance of product liability over the 
last few years, the Quality Controllers are 
increasingly being asked to re-test purchased 
specials on receipt, unless they can be furnished 
with a Certificate of Analysis. This can greatly add 
to the cost of purchased specials. The Quality 
Controllers have, however, agreed between 
themselves to accept the testing procedures of other 
N.H.S. specials units without the need to re-test. We 
can, and do, however, provide Certificates of 
Analysis if required. 
Some specials manufacturers offer a comprehensive 
~ervice, others specialise in a particular type of 
product. The N.H.S. licensed units, by and large 
offer a very comprehensive service, many of them 
being licensed to provide an aseptic service. Aseptic 
filling is a high cost operation, very labour intensive 
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and involving extensive validation and broth trials. 
Many commercial specials manufacturers do not 
offer this service for these reasons. 
Industry is offering a commercial, profit making 
service,itisouttomakemoney. TheN.H.S.specials 
units .are there to provide a service. They are able to 
respcnd rapidly to changing situations and are 
often in the forefront of developing new delivery 
syste:ns and admixtures. Many units also undertake 
Total Parenteral Nutrition, Central Intravenous 
Additive Services or C.I.V.A.S. and Patient 
Contolled Analgesia services. Although these are 
not strictly manufacturing procedures the expertise 
deve~oped in manufacturing, together with the 
high standards in the units make them the ideal 
place from which to conduct these essential services. 
National Health Service units have recently 
introduced a comprehensive service for the relief of 
post-operative pain. Where Total Parenteral 
Nutr~tion was the in vogue treatment of the 70's 
and the Central Intra Venous Additive Service that 
of the 80's, Patient Controlled Analgesia is now one 
of the fastest growing fields in modern medicine. 
The ability to let a patient control their own post-
operative pain allows a patient the unique 
opportunity to contribute to their own recovery 
and has been proven to increase recovery rates and 
the patient's feeling of well being. 
P.C.A. is administered either by pre-filled syringe, 
whim requires a syringe pump, a mini-bag, 
requiring an infusion pump, or, for ambulatory 
patients, an infusor device with a switch, worn on 
a west strap, powered by a small battery. The 
syringes, mini-bags, and infusors are all filled using 
an automatic dosing machine which acts like a 
med:.anical thumb. This device is used for all 
repetitive filling in our unit. As most of the 
analgesics used by this method are narcotics, either 
morphine or fentanyl, either alone or in combination 
with other substances, it is important to realize that 
thesE devices are pre-set. It is not possible for the 
patient to exceed the required dose either by 
increasing the volume of the metered dose or by 
decreasing the interval between doses. The patients 
however, can control their own pain when they 
need it and not when the nurse or doctor has the 
time to give them relief. 
Also. over the past 10 years the N.H.S. specials 
units have been working together to rationalize the 
product list within their units and thus reduce 
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duplication of effort. In the early 1980's the Regional 
Pharmaceutical Officers set up several sub-
committeesdealingwithDruginformation,Quality 
Control, Radiopharmacy, Education and 
Production and asked for representatives from 2ach 
region in each discipline. The Pharmaceutical 
Production Committee has been instrumental in 
rationalizing production, especially of sterile 
products, within the N.H.S. It is due to the wo::k of 
this committee that several units have taken over 
the roll of national supplier for certain items. 
At our sterile unit in Belfast we produce, on a 
national scale, various strengths of Baclofen either 
as ampoules or as vials for refilling implanted 
reservoirs associated with a miniature pumping 
device to give patient controlled relief f::-om 
neurological spasticity. The royal Victoria Hospital 
was one of the first units in the country to pioneer 
this treatment, and, as the shelf life of Baclofen in 
normal saline has been found to be only 9 months 
and the 12ml vials will refill a pump for the pe::iod 
of 2 to 3 months, the demand within any single :mit 
is not enormous and it is more economical for o:her 
hospitals to buy from us than to manufacture fl.eir 
own. In fact we supply these to over 2 dozen 
hospitals throughout the United kingdom and Eire. 
We are also the national supplier for Paraldehyde 
injection, a particularly nasty substance to work 
with, used to control seizures in status epilepticus. 
The Production Pharmacists sub-committee, with 
the collaboration of the Quality Control and 
Radiopharmacy sub-committees have, this year, 
set up, in conjunction with Leeds University an 
MSc in Pharmaceutical Technology and Quality 
assurance to ensure a constant renewal of 
pharmacists qualified to take over the technical 
jobs within pharmacy. This has become vital as, with 
the decrease in the number of production units and 
their associated quality control units, it is now not 
every pre-registration graduate who has more than 
passing contact with one of these special ties and has 
the chance of first hand experience. 
It is also hoped that this course will lead to 
registration as a Qualified Person. Although this is 
not,atthemoment,necessaryfor a Qualified Person 
to be named on the application for a "Specials" 
license, there is no guarantee that this will continue. 
The Market Economy 
In addition the Market Economy has come to the 
N.H.S. Although they are not producing specials 
primarily to make money and some units see it as a 
form of income generation, N.H.S. units are not 
allowed to make a loss. Production units are required 
to be self-financing. Staff costs, overheads, capital 
charges and repair and replacement of equipment 
must be financed by sales. This has led to production 
managers having to assume a more business like 
approach to their enterprises. This is made more 
difficult by the embargo on advertising by spec~als 
units. It is a requirement of the specials license that, 
although the service provided can be advertised, 
specific products must not be advertised and can 
only be supplied on receipt of an unsolicited order. 
It is from the need to advertise that I get the title of 
my paper. Due to the need to be self-financing, we 
need to advertise our services. The Producton 
Pharmacists Committee have coined the lcgo 
"We've been doing it for years .... " and now use it on 
all their promotional literature. 
At first sight the embargo on advertising 
specific products may seem unreasonable but 
if you think about it logically, if you were able 
to advertise an unlicensed drug, then what 
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would be the point of applying for an expensive 
product license. 
It is however, not illegal for a specials manufacturer 
to make a drug for which there is a licensed 
alternative.Manynewproductsstartlifeasspecials 
madeinN.H.S. units. From these beginnings,having 
proved their efficacy, they go on to licensed 
products. Industry jumping on the N.H.S. 
bandwagon. In some cases a hospital specials unit 
has been making a preparation for years when a 
licensed product becomes available. The unit will 
only cease to manufacture when the customer no 
bnger requires the drug. This usually only occurs 
when prescribing patterns change or the licensed 
alternative is cheaper, definitely not always the 
case. 
In the very odd case, an N.H.S. produced drug may 
ce more expensive but still required. It is the 
prerogative of the doctor to have the drug he requires 
and if he has been working successfully with the 
N.H.S. produced drug for a number of years, he 
may be loathe to change. Although economic 
restraints are now being applied, it is generally 
accepted that if a doctor want something badly 
enough, he will get it. 
-
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Where Do W_e Go Next? 
We are definitely seeing an increase in the 
requirement for injections in pre-filled 
syringes, especially for use in emergency 
situations. Also, the use of mini-bags seems to 
be on the increase and most new autoclaves 
are fitted with plastic bag cycles. Having said 
that, the N.H.S. is one of the few services that 
is now able to supply large volume infusions 
in glass rather than plastic and this is essential 
for some preparations. 
On the non-sterile front, casualty and take home 
packs are ever increasing and in mainland hospitals, 
pre-packs for out-patient dispensing are always 
required. In Northern Ireland drugs are not given 
from outpatient clinics, the patient is instead 
furnished with a prescription. We are also seeing an 
increase in the use of suppositories and the need for 
medication to be given in a liquid form. "Specials" 
units are developing and manufacturing more and 
more of these 
Conclusion 
National Health Service specials units will never 
be able to compete with industry on a commercial 
scale, neither should they attempt to do so. 
However, they can, and do offer a high quality, 
comprehensive service, able to respond quickly 
and efficiently to the needs of the health service. 
They are able to do this by harnessing their expertise 
to those areas which it is not commercially viable 
for industry to tackle and, by their increasing 
awareness of the commercial necessity of being 
self-financing, they are able to provide this service 
at a competitive price whilst covering their costs. 
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